Malonyl-CoA

Identification

Generic Name
Malonyl-CoA
DrugBank Accession Number
DB04524
Background

A coenzyme A derivative which plays a key role in the fatty acid synthesis in the cytoplasmic and microsomal systems.

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 853.58
Monoisotopic: 853.115602295
Chemical Formula
C24H38N7O19P3S
Synonyms
  • Coenzyme A, S-(hydrogen propanedioate)
  • Malonyl coenzyme A
  • S-(Hydrogen malonyl)coenzyme A

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
U3-oxoacyl-[acyl-carrier-protein] synthase 3Not AvailableEscherichia coli (strain K12)
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
PathwayCategory
Malonic AciduriaDisease
Methylmalonic Aciduria Due to Cobalamin-Related DisordersDisease
Malonyl-CoA Decarboxylase DeficiencyDisease
Pyruvate Kinase DeficiencyDisease
Propanoate MetabolismMetabolic
Pyruvate MetabolismMetabolic
Leigh SyndromeDisease
Pyruvate Dehydrogenase Complex DeficiencyDisease
Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency)Disease
Fatty Acid BiosynthesisMetabolic
Primary Hyperoxaluria II, PH2Disease
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as acyl coas. These are organic compounds containing a coenzyme A substructure linked to an acyl chain.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Fatty acyl thioesters
Direct Parent
Acyl CoAs
Alternative Parents
Coenzyme A and derivatives / Purine ribonucleoside diphosphates / Pentose phosphates / Ribonucleoside 3'-phosphates / Beta amino acids and derivatives / Glycosylamines / 6-aminopurines / Monosaccharide phosphates / Organic pyrophosphates / Aminopyrimidines and derivatives
show 21 more
Substituents
1,3-dicarbonyl compound / 6-aminopurine / Alcohol / Alkyl phosphate / Amine / Amino acid / Amino acid or derivatives / Aminopyrimidine / Aromatic heteropolycyclic compound / Azacycle
show 50 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
malonyl-CoAs (CHEBI:15531)
Affected organisms
Not Available

Chemical Identifiers

UNII
LNB9YCJ9F9
CAS number
524-14-1
InChI Key
LTYOQGRJFJAKNA-DVVLENMVSA-N
InChI
InChI=1S/C24H38N7O19P3S/c1-24(2,19(37)22(38)27-4-3-13(32)26-5-6-54-15(35)7-14(33)34)9-47-53(44,45)50-52(42,43)46-8-12-18(49-51(39,40)41)17(36)23(48-12)31-11-30-16-20(25)28-10-29-21(16)31/h10-12,17-19,23,36-37H,3-9H2,1-2H3,(H,26,32)(H,27,38)(H,33,34)(H,42,43)(H,44,45)(H2,25,28,29)(H2,39,40,41)/t12-,17-,18-,19+,23-/m1/s1
IUPAC Name
3-[(2-{3-[(2R)-3-[({[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)oxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)methyl]-2-hydroxy-3-methylbutanamido]propanamido}ethyl)sulfanyl]-3-oxopropanoic acid
SMILES
CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)N1C=NC2=C1N=CN=C2N)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O

References

General References
Not Available
KEGG Compound
C00083
PubChem Compound
644066
PubChem Substance
46506952
ChemSpider
559121
ChEBI
15531
ChEMBL
CHEMBL1234355
ZINC
ZINC000008551112
PDBe Ligand
MLC
Wikipedia
Malonyl-CoA
PDB Entries
1cml / 1hnj / 2e1t / 2f3x / 2q78 / 2xiq / 2xr7 / 3nyr / 4a0z / 5ab7
show 5 more

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.8 mg/mLALOGPS
logP-0.62ALOGPS
logP-6.2Chemaxon
logS-2.4ALOGPS
pKa (Strongest Acidic)0.83Chemaxon
pKa (Strongest Basic)4.92Chemaxon
Physiological Charge-5Chemaxon
Hydrogen Acceptor Count19Chemaxon
Hydrogen Donor Count10Chemaxon
Polar Surface Area400.93 Å2Chemaxon
Rotatable Bond Count22Chemaxon
Refractivity178.55 m3·mol-1Chemaxon
Polarizability75.33 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.5354
Blood Brain Barrier-0.8702
Caco-2 permeable-0.7258
P-glycoprotein substrateSubstrate0.7289
P-glycoprotein inhibitor INon-inhibitor0.7344
P-glycoprotein inhibitor IINon-inhibitor0.9939
Renal organic cation transporterNon-inhibitor0.9638
CYP450 2C9 substrateNon-substrate0.7799
CYP450 2D6 substrateNon-substrate0.7987
CYP450 3A4 substrateSubstrate0.5592
CYP450 1A2 substrateNon-inhibitor0.8091
CYP450 2C9 inhibitorNon-inhibitor0.7975
CYP450 2D6 inhibitorNon-inhibitor0.8382
CYP450 2C19 inhibitorNon-inhibitor0.7706
CYP450 3A4 inhibitorNon-inhibitor0.7851
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8953
Ames testNon AMES toxic0.6473
CarcinogenicityNon-carcinogens0.8502
BiodegradationNot ready biodegradable0.9867
Rat acute toxicity2.6856 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9742
hERG inhibition (predictor II)Non-inhibitor0.6159
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0000000090-cc2ea800906e39eb5f08
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0000000090-487b7cd8f7bd2fda6371
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00kk-1104100390-e366298c77f27b1aa114
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-008a-9000000570-91477434d81ab643b09a
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0feb-5400132940-b2713faf0e1ff98f6ae8
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-1119000000-fd6135fb321bf89ee72f
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-277.8055902
predicted
DarkChem Lite v0.1.0
[M-H]-242.21825
predicted
DeepCCS 1.0 (2019)
[M+H]+278.6032902
predicted
DarkChem Lite v0.1.0
[M+H]+243.94199
predicted
DeepCCS 1.0 (2019)
[M+Na]+276.8319902
predicted
DarkChem Lite v0.1.0
[M+Na]+250.27092
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Beta-ketoacyl-acyl-carrier-protein synthase iii activity
Specific Function
Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-ACP. Catalyzes the first condensation reaction which initiates fatty acid...
Gene Name
fabH
Uniprot ID
P0A6R0
Uniprot Name
3-oxoacyl-[acyl-carrier-protein] synthase 3
Molecular Weight
33514.78 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52